310 related articles for article (PubMed ID: 16091741)
1. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs.
Baker EK; Johnstone RW; Zalcberg JR; El-Osta A
Oncogene; 2005 Dec; 24(54):8061-75. PubMed ID: 16091741
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation of multidrug resistance 1 gene expression: profiling CpG methylation status using bisulphite sequencing.
Baker EK; El-Osta A
Methods Mol Biol; 2010; 596():183-98. PubMed ID: 19949925
[TBL] [Abstract][Full Text] [Related]
3. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment.
Tada Y; Wada M; Kuroiwa K; Kinugawa N; Harada T; Nagayama J; Nakagawa M; Naito S; Kuwano M
Clin Cancer Res; 2000 Dec; 6(12):4618-27. PubMed ID: 11156211
[TBL] [Abstract][Full Text] [Related]
4. Differential modulation of nuclear texture, histone acetylation, and MDR1 gene expression in human drug-sensitive and -resistant OV1 cell lines.
Yatouji S; El-Khoury V; Trentesaux C; Trussardi-Regnier A; Benabid R; Bontems F; Dufer J
Int J Oncol; 2007 Apr; 30(4):1003-9. PubMed ID: 17332941
[TBL] [Abstract][Full Text] [Related]
5. Redundancy of biological regulation as the basis of emergence of multidrug resistance.
Shtil AA; Azare J
Int Rev Cytol; 2005; 246():1-29. PubMed ID: 16164965
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
El-Khoury V; Breuzard G; Fourré N; Dufer J
Br J Cancer; 2007 Aug; 97(4):562-73. PubMed ID: 17667922
[TBL] [Abstract][Full Text] [Related]
8. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
Zhang Y; Fatima N; Dufau ML
Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
[TBL] [Abstract][Full Text] [Related]
9. Involvement of MyoD and PEA3 in regulation of transcription activity of MDR1 gene.
Zhao Y; Liu J; Hong Q; Yang C; Chen L; Chen Y; Wang Q; Zhao K; Jin W
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):900-7. PubMed ID: 20980337
[TBL] [Abstract][Full Text] [Related]
10. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.
Xiao JJ; Huang Y; Dai Z; Sadée W; Chen J; Liu S; Marcucci G; Byrd J; Covey JM; Wright J; Grever M; Chan KK
J Pharmacol Exp Ther; 2005 Jul; 314(1):467-75. PubMed ID: 15833893
[TBL] [Abstract][Full Text] [Related]
11. Hypothesizing that histone deacetylase inhibitors can be used to reverse multiple drug resistance.
Jiang ZP; Xu P; Wang GP; Zhao XL; Chen FP
Med Hypotheses; 2010 Jan; 74(1):92-4. PubMed ID: 19700246
[TBL] [Abstract][Full Text] [Related]
12. The clinical application of targeting cancer through histone acetylation and hypomethylation.
Gilbert J; Gore SD; Herman JG; Carducci MA
Clin Cancer Res; 2004 Jul; 10(14):4589-96. PubMed ID: 15269129
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
Teodoridis JM; Strathdee G; Brown R
Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
[TBL] [Abstract][Full Text] [Related]
14. Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor.
Re GG; Willingham MC; el Bahtimi R; Brownlee NA; Hazen-Martin DJ; Garvin AJ
Mod Pathol; 1997 Feb; 10(2):129-36. PubMed ID: 9127318
[TBL] [Abstract][Full Text] [Related]
15. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients.
Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
Vet J; 2014 Jan; 199(1):103-9. PubMed ID: 24332606
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
18. New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP130 protein.
Labialle S; Dayan G; Gayet L; Rigal D; Gambrelle J; Baggetto LG
Nucleic Acids Res; 2004; 32(13):3864-76. PubMed ID: 15272088
[TBL] [Abstract][Full Text] [Related]
19. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes.
Kaszubiak A; Holm PS; Lage H
Int J Oncol; 2007 Aug; 31(2):419-30. PubMed ID: 17611700
[TBL] [Abstract][Full Text] [Related]
20. 5-Azacytidine modulates the response of sensitive and multidrug-resistant K562 leukemic cells to cytostatic drugs.
Efferth T; Futscher BW; Osieka R
Blood Cells Mol Dis; 2001; 27(3):637-48. PubMed ID: 11482878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
